Fetroja® – Breakpoints

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the US Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information.**

Summary

- The various breakpoints for cefiderocol are listed below:
  - CLSI breakpoints (**Table 1**)[1]
  - FDA-approved breakpoints (**Table 2**)[2]
  - EUCAST breakpoints (**Table 3**)[3]

Fetroja® – Breakpoints

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the US Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information.**

Cefiderocol Breakpoints

Table 1. CLSI Breakpoints for Cefiderocol[1]

Pathogen[a]	MIC Breakpoints (µg/mL)			Zone Diameter[b] Breakpoints (nearest whole mm)		
	Susceptible	Intermediate	Resistant	Susceptible	Intermediate	Resistant
Enterobacterales	≤4	8[c]	≥16	≥16	9–15[c]	≤8
Pseudomonas aeruginosa	≤4	8[c]	≥16	≥18	13–17[c]	≤12
Acinetobacter baumannii complex	≤4	8	≥16	≥15[d]	–	–
Stenotrophomonas maltophilia[e]	≤1	–	–	≥17	–	

Breakpoints are based on a dosage regimen of 2 g every 8 h administered over 3 h.
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; g, grams; h, hours; MIC, minimum inhibitory concentration; PD, pharmacodynamics; PK, pharmacokinetics.
[a]The accuracy and reproducibility of cefiderocol testing results by disk diffusion and broth microdilution are markedly affected by iron concentration and inoculum preparation and may vary by disk and media manufacturer. Depending on the type of variance observed, false-resistant or false-susceptible results may occur. Testing subsequent isolates is encouraged. Discussion with prescribers and antimicrobial stewardship members regarding the potential for inaccuracies is recommended.
[b]Disk content for cefiderocol is 30 µg.
[c]Designation for agents that have the potential to concentrate in the urine.
[d]Disk diffusion zone diameters ≤14 mm should not be interpreted or reported because zone diameters ≤14 mm occur with resistant, intermediate, and susceptible isolates. For isolates with zone diameters ≤14 mm, do not report cefiderocol without performing a MIC test.
[e]Breakpoints are based on PK/PD properties, MIC distributions, and limited clinical data.

Fetroja® – Breakpoints

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the US Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information.**

Cefiderocol Breakpoints (Cont.)

Table 2. FDA-Approved Breakpoints for Cefiderocol[2]

Pathogen	MICs (µg/mL)			Disk Diffusion (zone diameter in mm)		
	Susceptible	Intermediate	Resistant	Susceptible	Intermediate	Resistant
Enterobacterales[a,b]	≤4	8[c]	≥16	≥16	9–15[c]	≤8
P. aeruginosa	≤1	2	≥4	≥22	13–21	≤12
A. baumannii complex	≤1	2	≥4	≥19	12–18	≤11
S. maltophilia	≤1[d]	–	–	≥17	–	–

Abbreviations: cUTI, complicated urinary tract infection; FDA, US Food and Drug Administration; HABP, hospital-acquired bacterial pneumonia; MIC, minimum inhibitory concentration; PD, pharmacodynamics; PK, pharmacokinetics; VABP, ventilator-associated bacterial pneumonia.
[a]Clinical efficacy was shown for *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Enterobacter cloacae* complex in patients with cUTIs.
[b]Clinical efficacy was shown for *E. coli*, *K. pneumoniae*, *E. cloacae* complex, and *Serratia marcescens* in patients with HABP and VABP.
[c]Designation for agents that have the potential to concentrate in the urine.
[d]Breakpoints are based on PK/PD properties, MIC distributions, and limited clinical data.

Fetroja® – Breakpoints

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the US Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information.**

Cefiderocol Breakpoints (Cont.)

Table 3. EUCAST Breakpoints for Cefiderocol[3]

Pathogen	MIC Breakpoints[a] (µg/mL)		Zone Diameter[b] Breakpoints (mm)		
	Susceptible	Resistant	Susceptible	Resistant	Area of Technical Uncertainty
Enterobacterales[c]	≤2	>2	≥23	<23	21–23
P. aeruginosa	≤2	>2	≥22	<22	20–21
S. maltophilia	Note[d]	Note[d]	Note[d]	Note[d]	–
Acinetobacter spp.	Note[e]	Note[e]	Note[e]	Note[e]	–

Abbreviations: ESBL, extended-spectrum β-lactamases; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration; PD, pharmacodynamics; PK, pharmacokinetics.

[a]Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth, and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.

[b]Disk content for cefiderocol is 30 µg.

[c]Breakpoints for Enterobacterales will detect all clinically important resistance mechanisms (including ESBL and plasmid-mediated AmpC). Some isolates that produce β-lactamases are susceptible to 3rd or 4th generation cephalosporins with these breakpoints and should be reported as tested (ie, the presence or absence of an ESBL does not in itself influence the categorization of susceptibility). ESBL detection and characterization are recommended for public health and infection control purposes.

[d]The *in vitro* activity of cefiderocol against *S. maltophilia* is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1–2 mg/L have acquired resistance mechanisms. Little clinical data exist regarding clinical outcomes for these isolates; however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant to this agent.

[e]The *in vitro* activity of cefiderocol against *A. baumannii* group is comparable to the activity of the agent against Enterobacterales and there are also animal data to suggest efficacy. However, there are insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1–2 mg/L have acquired resistance mechanisms. Little clinical data exist regarding clinical outcomes for these isolates; however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant to this agent.

Fetroja® – Breakpoints

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the US Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information.**

Relevant Prescribing Information

Fetroja® is indicated in patients 18 years of age or older for the treatment of:[4]

- Complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms:
  - *Escherichia coli*
  - *Klebsiella pneumoniae*
  - *Proteus mirabilis*
  - *Pseudomonas aeruginosa*
  - *Enterobacter cloacae* complex
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms:
  - *Acinetobacter baumannii* complex
  - *Escherichia coli*
  - *Enterobacter cloacae* complex
  - *Klebsiella pneumoniae*
  - *Pseudomonas aeruginosa*
  - *Serratia marcescens*

Fetroja is contraindicated in:[4]

- Patients with a known history of severe hypersensitivity to cefiderocol or other beta-lactam antibacterial drugs, or any other component of **Fetroja**

Please read the attached **Fetroja Full Prescribing Information**

Fetroja® – Breakpoints

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the US Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information.**

Abbreviations

CLSI	Clinical and Laboratory Standards Institute	HABP	hospital-acquired bacterial pneumonia
cUTI	complicated urinary tract infection	MIC	minimum inhibitory concentration
ESBL	extended-spectrum β-lactamases	PD	pharmacodynamics
EUCAST	European Committee on Antimicrobial Susceptibility Testing	PK	pharmacokinetics
FDA	US Food and Drug Administration	US	United States
g	grams	VABP	ventilator-associated bacterial pneumonia
h	hours		

References

1. Clinical and Laboratory Standards Institute [Website]: Performance Standards for Antimicrobial Susceptibility Testing (36th edition) CLSI M100 (updated January 26, 2026). Last accessed October 21, 2026. Available at: [Web Link]
2. US Food and Drug Administration [Website]: Cefiderocol Injection (updated February 05, 2026). Last accessed October 21, 2026. Available at: [Web Link]
3. European Committee on Antimicrobial Susceptibility Testing [Website]: Clinical Breakpoint Tables (updated June 24, 2026). Last accessed October 21, 2026. Available at: [Web Link]
4. Fetroja® (cefiderocol) for injection, for intravenous use [Prescribing Information]. Shionogi Inc.

Enclosure

Fetroja® (cefiderocol) for injection, for intravenous use [Prescribing Information]. Shionogi Inc.